Back Hepatitis B Hepatitis B Topics HBV Treatment Drug Advisories & Warnings

FDA: Do Not Mix Hepatitis B Drug Adefovir with Stribild HIV Combo Pill

The U.S. Food and Drug Administration (FDA) last week announced an update to the label information for adefovir dipivoxil (Hepsera), adding the 4-in-1 antiretroviral combination pill Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) to the list of other products that should not be co-administered with adefovir.alt

Read more:

Do Not Use Telbivudine (Tyzeka) with Pegasys for Hepatitis B, FDA Warns

The U.S. Food and Drug Administration (FDA) last week announced revisions to the product label for the nucleoside analog telbivudine (Tyzeka), indicating that it should not be used with pegyalted interferon alfa-2a (brand name Pegasys) for the treatment of hepatitis B because the combination can cause peripheral neuropathy, or nerve damage.alt

Read more:

Telbivudine Label Adds Resistance Warning

Package labeling for the hepatitis B drug telbivudine (Tyzeka) was recently changed to add information about the risk of drug resistance and a recommendation for monitoring after 6 months of treatment.

Read more: